Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Rolf A. Stahel, Enriqueta Felip et al.|The Lancet Respiratory Medicine|2017

Cited by 184